BTIG raises Abivax stock price target to $175 on safety data

BTIG raised its ABIVAX (ABVX) price target to $175 from $150 while keeping a Buy rating after ABTECT Maintenance Part 2 safety updates for obefazimod. The data showed 37.2% clinical remission at Week 44 (vs non-induction responders) and 34.5% endoscopic remission, and BTIG increased ulcerative colitis probability of success to 95% (from 90%)—but noted malignancy cases (7 in the 50mg cohort) leading other firms to cut targets (e.g., Wolfe to $136 and Truist to $135). Management remains on track for an ulcerative colitis NDA submission in 4Q 2026, with Phase 2b ENHANCE-CD results expected mid-2027, keeping the overall investor view mixed.

Analysis

This is still a long-dated de-risking story, not an earnings story. The market’s real variable is whether ABVX can sustain a high probability-of-approval narrative without the safety overhang forcing a heavier discount rate or an interim financing; for a pre-revenue biotech, that dilution risk is often more important than the clinical readthrough itself.

On competitive dynamics, the signal is less about immediate displacement and more about whether obefazimod can credibly enter a crowded UC maintenance market without forcing physicians to give up established safety familiarity. If malignancy monitoring remains an open question, the likely winners are incumbents with already-de-risked safety/efficacy profiles such as ABBV, BMY, and TAK, because payers and prescribers tend to prefer known quantities when efficacy deltas are modest. That argues for limited near-term share gains even if the asset ultimately reaches the market.

The contrarian risk is that consensus may be anchoring on the upside of the remission data while underweighting how much of the valuation now depends on a clean follow-up safety package and FDA receptivity over the next 12-24 months. The stock has already repriced materially on the probability-of-success narrative, so incremental target hikes may have diminishing impact unless the company can remove the malignancy uncertainty or show stronger comparative durability. What would falsify the cautious view: a clean FDA interaction, no further safety signal on extended follow-up, and evidence that physicians see the drug as meaningfully differentiated versus biologics/JAKs rather than just "another option."

Key Decisions for Investors

• Avoid chasing ABVX on target-price upgrades; the better entry is after a post-rally pullback or after FDA feedback materially reduces the safety discount. Risk/reward is unfavorable above the recent high if the only new information is analyst model lift.
• Pair trade: long ABBV or BMY vs short ABVX as a way to express that established IBD franchises are safer beneficiaries of a slow adoption cycle. This is a 6-18 month relative-value expression, not a catalyst trade.
• If holding ABVX, consider financing with a defined-risk call spread rather than common stock into the 2026 NDA window; the thesis is binary and the hidden risk is dilution, not just clinical failure.
• Set a watch item on future safety follow-up and any FDA communication; if malignancy incidence remains elevated or labeling concerns appear, re-rate ABVX lower quickly, especially on any move back toward the 52-week high.
• No actionable view on TGT from this item; absent a direct therapeutic, regulatory, or supply-chain link, it should not be traded off this news.